ToeFX Light Therapy for Chronic Venous Leg Ulcers
Adjunctive ToeFX Photodynamic Therapy for Chronic Venous Leg Ulcers: A Single-Arm, Open-Label Pilot Feasibility Study
Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.
A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.
The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.
This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.
The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.
A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.
ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.
This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Ahmed Kayssi, MD MSc FRCSC
- Número de teléfono: (416) 691-2030
- Correo electrónico: ahmed.kayssi@sunnybrook.ca
Ubicaciones de estudio
-
-
Ontario
-
Toronto, Ontario, Canadá, M4L 3Y3
- East Toronto Vascular Clinic
-
Contacto:
- Ahmed Kayssi, MD MSc FRCSC
- Número de teléfono: (416) 691-2030
- Correo electrónico: ahmed.kayssi@sunnybrook.ca
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age 18 years or older
- Able to attend weekly visits for up to 12 weeks
- Chronic venous leg ulcer (CEAP C6) of the lower extremity
- Ulcer duration of 4 weeks or more
- Ulcer size between 1 cm² and 20 cm² at baseline
- Receiving standard-of-care compression therapy, or eligible to initiate it
- Able to provide informed consent and comply with study procedures
Exclusion Criteria:
- Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
- Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
- Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
- Severe ischemia (ABI below 0.5) or poorly controlled diabetes (HbA1c above 10%)
- Heavy exudate requiring negative-pressure wound therapy
- Known photosensitivity or allergy to methylene blue or light-based therapies
- Immunosuppressive therapy, radiation or chemotherapy within the past 3 months, or active malignancy
- Pregnancy or lactation
- Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
- Participation in another interventional study within 30 days of screening
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Viabilidad del dispositivo
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: ToeFX Treatment
Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure |
Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Treatment adherence
Periodo de tiempo: Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions |
Baseline through Visit 12/ end of treatment (up to 12 weeks)
|
|
Safety: Adverse Events
Periodo de tiempo: Baseline through Healing Confirmation Visit (up to 14 weeks)
|
Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs |
Baseline through Healing Confirmation Visit (up to 14 weeks)
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percent Change in Wound Area From Baseline
Periodo de tiempo: Baseline, week 4, week 8, and week 12
|
Percent change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
|
Complete wound epithelialization
Periodo de tiempo: 12 weeks
|
Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician |
12 weeks
|
|
Time to complete wound healing
Periodo de tiempo: 12 weeks
|
Time (days) from baseline to complete epithelialization |
12 weeks
|
|
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
Periodo de tiempo: Baseline to 12 weeks/ end of treatment
|
Change in wound bed characteristics measured using the BWAT |
Baseline to 12 weeks/ end of treatment
|
|
Change in pain score
Periodo de tiempo: Baseline to 12 weeks/ end of treatment
|
Change in pain score (0-10 Numeric Rating Scale) |
Baseline to 12 weeks/ end of treatment
|
|
Change in health-related quality of life
Periodo de tiempo: 12 weeks/ end of treatment
|
Change in EQ-5D-5L score |
12 weeks/ end of treatment
|
|
Patient satisfaction
Periodo de tiempo: 12 weeks/ end of treatment
|
Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire |
12 weeks/ end of treatment
|
|
Clinician feasibility
Periodo de tiempo: 14 weeks or earlier if wound healing
|
Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow |
14 weeks or earlier if wound healing
|
|
Absolute Change in Wound Area From Baseline
Periodo de tiempo: Baseline, week 4, week 8, and week 12
|
Absolute change in wound area (cm²) from baseline |
Baseline, week 4, week 8, and week 12
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Ahmed Kayssi, MD MSc FRCSC, East Toronto Vascular Clinic
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- PRO04244160_ToeFX
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .